Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer

NCT ID: NCT05033769

Last Updated: 2023-04-18

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 82 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-03-11
• Study Completion Date: 2023-09-15

Brief Summary

After progression of disease after one chemotherapy, metastatic breast cancer patients will be randomized 1:1 to one of the following treatment arms:

Arm A. Eribulin Arm B. Paclitaxel

Blood draws for immune analysis will be performed before start of therapy, on day 1 of cycle 2 and on day 21 of cycle 4 (end of therapy) for the primary study aim. Patients will be treated under study conditions for a maximum of 4 therapy cycles.

Detailed Description

This is a prospective, randomized Phase IV study. Patients who progressed after one chemotherapy in the metastatic setting will be randomized 1:1 to one of the following treatment arms. Arm A. Eribulin 1.23 mg/m2 on days 1 and 8 q21d Arm B. Paclitaxel 80 mg/m2 on days 1, 8, and 15 q21d Blood draws for immune analysis will be performed before start of therapy on day 1 of cycle 1, on day 1 of cycle 2 (pre dose each) and on day 21 of cycle 4 (end of therapy) and assessed for the primary study aim. Patients will be treated under study conditions for a maximum of 4 therapy cycles.

Conditions

Breast Cancer Female; Neoplasm, Breast; Breast Cancer Metastatic

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Eribulin

Arm A. Eribulin 1.23 mg/m\^2, administered as an injection on day 1 and 8 q 21d for a maximum of 4 therapy cycles

Group Type: EXPERIMENTAL

Eribulin Injection [Halaven]

Intervention Type: DRUG

on days 1 and 8 q21d

Paclitaxel

Paclitaxel 80 mg/m\^2, administered as an injection on day 1, 8 and 15 q21d for a maximum of 4 therapy cycles

Group Type: ACTIVE_COMPARATOR

Paclitaxel injection

Intervention Type: DRUG

on days 1, 8, and 15 q21d

Interventions

Eribulin Injection [Halaven]

on days 1 and 8 q21d

Intervention Type: DRUG

Paclitaxel injection

on days 1, 8, and 15 q21d

Intervention Type: DRUG

Other Intervention Names

Eribulin; Paclitaxel

Eligibility Criteria

Inclusion Criteria

• Written informed consent prior to beginning of trial specific procedures
• Subject must be female and aged ≥ 18 years on day of signing informed consent
• ECOG 0-1
• Histologically confirmed, HER2 negative breast cancer determined by core biopsy of tumor lesion. Human epidermal growth factor receptor 2 (HER2) negativity is defined as either of the following by local laboratory assessment: In situ hybridization (ISH) non-amplified (ratio ≤ 2.2), or IHC 0 or IHC 1+.
• Indication for chemotherapy
• Previous therapy with one chemotherapy line
• Target lesion (RECIST 1.1)
• Adequate organ function defined as:

Creatinine Clearance > 50 ml/min ANC ≥ 1.5 x 10 3 /μL Thrombocytes > 100 x 10 3 /μL

Exclusion Criteria

• HER2 positive disease
• Indication for an anti-hormone treatment
• Active infection requiring systemic therapy.
• Active autoimmune disease or other diseases that requires systemic treatment with corticosteroids or immunosuppressive drugs.
• History of primary or acquired immunodeficiency (including allogenic organ transplant).
• Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).
• Severely impaired liver function (Child Pugh C)
• Hypersensitivity to study medication or any of its components
• Neuropathy (PNP) > Grade 2 (CTCAE 5.0)
• Congenital long QT syndrome
• Preexisting concomitant use of strong CYP3A4 and CYP2C8 inhibiting or inducing drugs
• Life expectancy of less than three months
• Pregnancy (contraception is required according tocontraceptive guidance)
• Lactation
• Known history of following infections: Human immunodeficiency virus (HIV), History of acute or chronic Hepatitis B or Hepatitis C
• Has received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted.
• Does not agree to blood collection

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Eisai GmbH

INDUSTRY

Sponsor Role: collaborator

Institut fuer Frauengesundheit

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Peter A Fasching, MD, Prof.

Role: STUDY_CHAIR

Department of Gynecology and Obstetrics, Erlangen University Hospital

Locations

Department of Gynecology, Tübingen University Hospital

Tübingen, Baden-Wurttemberg, Germany

Site Status: RECRUITING

Department of Gynecology and Obstetrics, Erlangen University Hospital

Erlangen, Bavaria, Germany

Site Status: RECRUITING

Countries

Germany

Central Contacts

AIRE Study manager

Role: CONTACT

aire@ifg-erlangen.de

+49 (0) 9131 927 9578

Facility Contacts

Andreas Hartkopf, MD, Prof.

Role: primary

andreas.hartkopf@med.uni-tuebingen.de

+49 07071 29 82211

Peter A Fasching, Prof. Dr.

Role: primary

peter.fasching@uk-erlangen.de

+49 9131 85 ext. 43470

Other Identifiers

2020-001938-35

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

AGO-B-049

Identifier Type: OTHER

Identifier Source: secondary_id

IFG-06-2019

Identifier Type: -

Identifier Source: org_study_id